Navigation Links
Laureate Pharma to Add More Manufacturing Capacity
Date:9/18/2008

- Laureate To Add Single-Use Bioreactor (S.U.B.) To Its Portfolio Of Assets

-

PRINCETON, N.J., Sept. 18 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it is increasing its existing manufacturing capacity by adding two Single-Use Bioreactors (S.U.B.). Acquisition of a 250L and a 1000L S.U.B. will give Laureate greater flexibility in meeting the varying needs of its clients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

The S.U.B. is a single-use alternative to conventional stirred tank bioreactors. The S.U.B. consists of a permanent stainless steel outer support container and a S.U.B. Bioprocess Container (BPC(R)), integrated with an existing bioreactor control system. This makes the S.U.B. a flexible, rapid and economic option to update or increase the bioreactor capacity. The S.U.B. will supplement Laureate's current single-use bioreactors -- Wave Bioreactors(R) and hollow-fiber systems -- as well as the conventional stainless steel stirred-tank bioreactors.

"We are excited about adding the S.U.B. to increase our bioreactor capacity. It is a scalable technology that will support the demand from our growing client base and meet their needs and manufacturing objectives," said Robert J. Broeze, Ph. D., President & Chief Executive Officer of Laureate. "The HyClone S.U.B. provides us with all the advantages of single-use bioprocessing, while maintaining aspect ratios and agitation mechanisms comparable to traditional stainless steel stirred-tank bioreactors."

About Laureate Pharma, Inc.

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or info@laureatepharma.com or visit http://www.laureatepharma.com.


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ARUP Laboratories ARUP Consult(R) Recognized as a Computerworld Honors Program Laureate
2. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
3. Laureate Pharma Reports Record Growth for 2007
4. Laureate Pharma Appoints Gary Swan as Vice President of Operations
5. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
6. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
7. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
8. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
9. DFB Sells Coria Labs to Valeant Pharmaceuticals
10. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
11. Pharmatek Announces Official Opening of New Highly-Potent & Cytotoxic Development and Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... HAMILTON, Bermuda , Dec. 5, 2016 ... leading clinical-stage biopharmaceutical company focused on the treatment of ... of intepirdine for the treatment of Alzheimer,s disease will ... Disease (CTAD) Meeting on Friday, December 9, 2016 in ... CTAD will show results of both simple and complex ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... to soon resume cervical and lumbar disc production, company President, Jake Lubinski will ... who are implanting the AxioMed disc in Cologne and Karlsruhe to discuss the ...
(Date:12/5/2016)... NxGen MDx announced today that it brought its NxGen Informed ... been able to improve customer service through shortened turnaround times and at ... , CEO of NxGen MDx. ... A decrease in turnaround times by ... job opportunities at the Grand Rapid headquarters. The NxGen Informed ...
(Date:12/4/2016)... ... December 02, 2016 , ... A proposed five-year extension ... federally funded research and development is welcome news for the photonics community, say ... , As part of the National Defense Authorization Act (NDAA) compromise agreement finalized ...
Breaking Biology Technology:
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... Research and Markets has announced the addition of the "Biometrics ... The report forecasts the biometrics market ... CAGR of 12.28% during the period 2016-2020. The ... inputs from industry experts. The report covers the market landscape and ... a discussion of the key vendors operating in this market. ...
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
Breaking Biology News(10 mins):